Role of phosphodiesterase-4 on ethanol elicited locomotion and narcosis

Neuropharmacology. 2016 Feb:101:271-8. doi: 10.1016/j.neuropharm.2015.10.001. Epub 2015 Oct 9.

Abstract

The cAMP signaling pathway has emerged as an important modulator of the pharmacological effects of ethanol. In this respect, the cAMP-dependent protein kinase has been shown to play an important role in the modulation of several ethanol-induced behavioral actions. Cellular levels of cAMP are maintained by the activity of adenylyl cyclases and phosphodiesterases. In the present work we have focused on ascertaining the role of PDE4 in mediating the neurobehavioral effects of ethanol. For this purpose, we have used the selective PDE4 inhibitor Ro 20-1724. This compound has been proven to enhance cellular cAMP response by PDE4 blockade and can be administered systemically. Swiss mice were injected intraperitoneally (i.p.) with Ro 20-1724 (0-5 mg/kg; i.p.) at different time intervals before ethanol (0-4 g/kg; i.p.) administration. Immediately after the ethanol injection, locomotor activity, loss of righting reflex, PKA footprint and enzymatic activity were assessed. Pretreatment with Ro 20-1724 increased ethanol-induced locomotor stimulation in a dose-dependent manner. Doses that increased locomotor stimulation did not modify basal locomotion or the suppression of motor activity produced by high doses of this alcohol. Ro 20-1724 did not alter the locomotor activation produced by amphetamine or cocaine. The time of loss of righting reflex evoked by ethanol was increased after pretreatment with Ro 20-1724. This effect was selective for the narcotic effects of ethanol since Ro 20-1724 did not affect pentobarbital-induced narcotic effects. Moreover, Ro 20-1724 administration increased the PKA footprint and enzymatic activity response elicited by ethanol. These data provide further evidence of the key role of the cAMP signaling pathway in the central effects of ethanol.

Keywords: Ethanol; PDE4; PKA; cAMP.

MeSH terms

  • 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / pharmacology
  • Animals
  • Brain / drug effects
  • Brain / enzymology
  • Central Nervous System Depressants / blood
  • Central Nervous System Depressants / toxicity*
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Cyclic Nucleotide Phosphodiesterases, Type 4 / metabolism*
  • Dose-Response Relationship, Drug
  • Ethanol / blood
  • Ethanol / toxicity*
  • Mice
  • Motor Activity / drug effects*
  • Phosphodiesterase Inhibitors / pharmacology
  • Statistics, Nonparametric
  • Stupor / chemically induced*
  • Stupor / drug therapy
  • Stupor / enzymology*
  • Time Factors

Substances

  • Central Nervous System Depressants
  • Phosphodiesterase Inhibitors
  • 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone
  • Ethanol
  • Cyclic AMP-Dependent Protein Kinases
  • Cyclic Nucleotide Phosphodiesterases, Type 4